Bo Jesper Hansen
Chairman of the Board, Board member since 2009
Since 1998 and until mid January 2010 Dr Hansen was the CEO and President of Swedish Orphan International Group of Companies consisting of the subsidiaries in Sweden, Denmark, Finland, Norway, the Baltic States, the UK, Germany, France, Spain, Italy, the CEE and Russia. Dr Hansen has been in Swedish Orphan International AB since 1993 having initially established the subsidiaries in Norway and Denmark and was also responsible for the current expansion into Europe. Dr Hansen has held several executive positions within the company before becoming Vice President for the parent company and later on being appointed the company CEO. During this period he has also co-founded the Shared Clinic "The Prostate Clinic" in Denmark. Dr Hansen experience includes International Marketing and Contract negotiations, extensive knowledge within Regulatory, Pharmacovigilance, Medical Marketing and Business Development and he is very well connected and has close collaborations with persons involved in the Pharmaceutical Industry in general and in the Orphan Drug area in particular. Prior to joining Swedish Orphan International AB, Dr Hansen worked as a medical advisor for several of the biggest Pharmaceutical Companies through the privately owned and founded company Scandinavian Medical Research. Today, Dr Hansen acts as Vice Chairman of the board of Biovitrum AB (pupl) and as ordinary member of the board in CMC AB, Mipsalus ApS, and Zymenex A/S. Dr Hansen is a Medical doctor, PhD from the University of Copenhagen having significant research experience. Dr Hansen is the author of more than 40 publications in international peer-review scientific journals and is an experienced presenter at international scientific congresses.

Anders Gersel Pedersen
Board member since 2001
Dr Pedersen is Executive Vice President, Development at H. Lundbeck A/S. After earning his degree in medicine and holding Research Fellow positions at Copenhagen hospitals, Dr Pedersen worked for Eli Lilly for eleven years; ten of these as a director overseeing world-wide clinical research in oncology, before joining Lundbeck in 2000. At Lundbeck, Dr Pedersen is responsible for the development of the product pipeline including clinical and pharmaceutical research, regulatory affairs and pharmacovigilance. Dr Pedersen received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from the Copenhagen Business School. Dr Pedersen serves also on the Supervisory Boards of ALK-Abelló A/S and Genmab A/S (Deputy Chairman).

Anker Lundemose
Board member since 2010
Mr. Anker Lundemose is currently Executive Vice President of Corporate Development and Strategic Planning at OSI and Managing Director & President of OSI Investment Holding GmbH. Anker Lundemose is a serial biotech entrepreneur and co-founder of several companies including Symphogen A/S, Santaris Pharma A/S and Prosidion Ltd in the UK. Background spans academia, large pharma as well as biotech with positions held in both R&D, Business & Corporate Development as well as Executive Management. Executive Vice President of OSI Pharmaceuticals (NASDAQ:OSIP) since April 2005. Previously held positions at Prosidion Ltd as CEO and Novo Nordisk as Associate Director, Business Development & as Head of Diabetes Biology, Novo Nordisk and has served as member of the Board of Directors for Symphogen A/S and for Display Biotech Systems A/S. Currently Member of the Board of Directors in Topotarget A/S, Prosidion Limited, OSI Pharmaceuticals UK Limited, OSI Investment Holding GmbH & OSI Investment Management GmbH and further sits on the Advisory Board to Oxfordshire Bioscience Network. He received an MD in 1988 from University of Aarhus, Denmark and continued at University of Aarhus to 1992 as a Post Doctoral Fellow. During this period, in 1992, he was awarded a Wellcome Trust Fellowship at University of Birmingham, England. A Ph.D. degree (Molecular Microbiology) was obtained in 1990 and a Doctor of Science (Dr Med) degree in 1994, both from University of Aarhus, Denmark. Anker Lundemose holds a Diploma in "Management of Drug and Device Development" from Scandinavian International Management Institute (SIMI).

Ingelise Saunders
Board member since 2004
Mrs. Saunders is President and CEO of TD Vaccines A/S and ActionPharma A/S. Mrs. Saunders is a member of the Board of Alk-Abelló A/S, Scandinavian Life Science Venture AB, Evolva Holding SA and Nordic Vaccine A/S (Chairman). For 5 years Mrs. Saunders was the CEO of ACE BioSciences A/S, and for two and a half years, she was the CEO of Celltech Pharmaceuticals in the UK and a member of the Board of Celltech Group Plc. Prior to this Mrs. Saunders held a number of executive management positions during her 15 years of employment with Novo Nordisk. From 2002 to 2005, Mrs. Saunders served on the Board of Directors of UCB Nordic ApS and in 2005 she was a member of the Board of Directors of Alfalyse ApS. Mrs. Saunders holds a degree in Pharmacy from the Royal Danish School of Pharmacy and a Bachelor of Commerce degree in Marketing.

Jeffrey H. Buchalter
Board member since 2006
Mr. Jeffrey Buchalter is currently President and CEO of Archimedes Pharma Limited, a specialty pharmaceutical company marketing and selling an expanding portfolio of specialist products to hospital-based prescribers in major European territories and serves as a Director on the company's Board of Directors. Mr. Buchalter was previously President, CEO and a Board Director of Enzon Pharmaceuticals, Inc and Ilex Oncology, Inc. as well as Group Vice President and Global Head of the Worldwide Oncology at Pharmacia Corporation. During his career, Mr. Buchalter has also held positions at Wyeth and Schering-Plough Corporation. Moreover, Mr. Buchalter serves as Chairman of the Board of Directors of National Childhood Cancer Foundation. Mr. Buchalter received his B.S. in finance from Seton Hall University and his M.B.A. in marketing from Temple University.

Per Samuelsson
Board member since 2009
Mr. Per Samuelsson is a Partner with HealthCap, a venture capital fund and he is based in Stockholm, Sweden. Prior to joining Odlander Fredrikson / HealthCap in the year 2000, Mr. Samuelsson gained over 15 years of investment banking experience, mainly with Aros Securities in Sweden. In his most recent position with Aros Securities, as a Director in the firm's corporate finance department, he specialised in the areas of Merger Transactions, Initial Public Offerings and Equity Incentive Programs. Prior to this Mr. Samuelsson was head of Research, also at Aros Securities. Mr. Samuelsson received his M.Sc. in Engineering from the Institute of Technology in Linköping. Mr. Samuelsson currently holds positions in the following companies: Algeta ASA (board member), BioStratum Inc. (board member), Cardoz AB (board member), Nucleonics Inc. (board member) and Optivy AB (board member).